Sunday, 25 June 2017

No heart risks from Novartis’ Parkinson’s drug

Good news for drug manufacturing company Norvatis as U.S. health regulators
said on Monday that they found
no evidence of increased
cardiovascular risks related to
Novartis AG's treatment, Stalevo,
for Parkinson's disease.

Norvatis are the manufacturer of the drug Stalevo which is used for
treating Parkinson's disease. The story would have been different if
the FDA have discovered that their drug linked to any cardiovascular
disease.

No comments:

Post a Comment

More exercise leads to more youthful arteries

According to US research exercising two to three times a week (30 minutes per session) over a lifetime led to more youthful middle-sized ar...